Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical firm Celgene has invested an undisclosed amount in US-based immunometabolic cancer drug developer Kyn Therapeutics as part of a strategic collaboration deal that will also involve an upfront payment of $80m. Kyn had previously received $49m in series A funding from healthcare investment firm OrbiMed and venture capital firm Atlas Venture in December 2017.…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.